MCK McKesson Corporation

P/E 23.04
Forward P/E 19.3
Price/Sales 0.244
Beta 0.307
Div Yield 0.0039%
Market Cap --

Company Analysis

Latest News

Farallon Capital Management exits its $202.75M stake in McKesson Corp

In a recent SEC 13F filing, Farallon Capital Management disclosed the complete liquidation of its position in McKesson Corp (MCK) during the second quarter of...

🔴 McKesson is trading 4% down today amid Medical-Surgical adjusted operating profit falling 20%

McKesson is trading at $842.00, down 4.02%, after investors digested its August 5 earnings release, with concern focused on Medical-Surgical weakness. -...

McKesson's first quarter revenue beats estimates at $105.4B, prompting a raise in FY27 EPS guidance.

McKesson's first quarter revenue beats estimates at $105.4B, prompting a raise in FY27 EPS guidance.

McKesson reported first quarter fiscal 2027 revenue of $105.4 billion, an 8% year-over-year increase, and adjusted earnings of $9.93 per share, up 20%. The...

McKesson Corporation Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026

McKesson is expected to report Q2 2026 revenue of $104.25 billion and adjusted EPS of $9.44, with the current stock price of $850.02 trading below the average...

🟢 McKesson is trading 4.5% up today on rotation into healthcare and value stocks

McKesson is trading 4.5% up at $888.23 amid a broader market rotation into defensive, healthcare-linked names. • The stock is benefiting from a shift toward...

McKesson Boosts Dividend 15%, Extending Growth Streak to 10 Years

McKesson Boosts Dividend 15%, Extending Growth Streak to 10 Years

McKesson Corporation (NYSE:MCK) approved a 15% increase to its quarterly dividend. The payout rises from $0.82 to $0.94 per share. The dividend is payable on...

McKesson loses legal privilege, court cites good-faith defense in oncology case

McKesson loses legal privilege, court cites good-faith defense in oncology case

A federal court ruled against McKesson Corporation in a False Claims Act lawsuit, potentially broadening the scope of discovery. This decision may permit...

McKesson Announces Retirement of Chief Strategy Officer and Appoints Successor

McKesson Announces Retirement of Chief Strategy Officer and Appoints Successor

McKesson Corporation announced the upcoming retirement of its Executive Vice President, Chief Strategy and Business Development Officer, Thomas L. Rodgers. To...

🟢 MCK is trading 5.4% up today, rebounding from recent weakness

MCK is trading at $784.99 (5.4% up) in pre-market, rebounding from recent multi-day weakness despite broader index futures trading lower. • No fresh...

McKesson Subsidiary Enters into $2.25 Billion Senior Secured Term Loan Facility

McKesson Subsidiary Enters into $2.25 Billion Senior Secured Term Loan Facility

McKesson Corporation (MCK) disclosed that its subsidiary, McKesson Medical-Surgical Top Holdings, Inc., has entered into an amendment to its existing credit...

McKesson closes $1.25B Apollo deal, paving way for medical unit spinoff

McKesson closes $1.25B Apollo deal, paving way for medical unit spinoff

McKesson Corporation completed its transaction with Apollo Funds on June 1, 2026. Apollo invested $1.25 billion for a minority stake in the Medical-Surgical...

McKesson Medical Unit Prices $2.25 Billion Loan, Targeting Standalone IPO

McKesson Medical Unit Prices $2.25 Billion Loan, Targeting Standalone IPO

McKesson Corporation’s Medical-Surgical Solutions (MMS) unit priced a $2.25 billion leveraged loan on June 3, 2026. The financing establishes an independent...

McKesson Gains $1.65 Billion Stake From Norway’s Sovereign Wealth Fund

McKesson Gains $1.65 Billion Stake From Norway’s Sovereign Wealth Fund

Norges Bank established a new position in McKesson Corporation according to recent 13F regulatory filings. The sovereign wealth fund purchased 2,012,870...

McKesson Corporation Q1 2026 Earnings Preview: What Analysts Expect on May 13, 2026

For the reporting period ending March 31, 2026, analysts expect McKesson to post consensus revenue of $101.40 billion and an adjusted EPS of $11.56, while the...

McKesson's fourth quarter fiscal 2026 EPS of $11.69 beat estimates, driven by strong growth in its Oncology segment.

McKesson's fourth quarter fiscal 2026 EPS of $11.69 beat estimates, driven by strong growth in its Oncology segment.

McKesson reported fourth quarter fiscal 2026 revenues of $96.3 billion, a 6% increase year-over-year, with adjusted EPS growing 16% to $11.69. For the full...

McKesson Corporation Q1 2026 Earnings Preview: What Analysts Expect on May 07, 2026

McKesson is expected to report Q1 2026 revenue of $101.61 billion and EPS of $11.56, with the current stock price of $807.85 trading significantly below the...